Back to search

Article

Homoharringtonine overcomes the negative impact of genetic patterns on venetoclax plus azacitidine regimen in relapsed/refractory acute myeloid leukemia: a multi-center, cohort study

2023-07-13

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold> The response of venetoclax (VEN)-based therapy is closely associated with genetic patterns and combining regimens in acute myeloid leukemia (AML). Whether other agents added to VEN plus hypomethylating agents (HMA) regimen could overcome the negative impact of genetic patterns on response remains unclear. <bold>Methods</bold> A multi-center, cohort study of the r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f23328fe-cf5c-5f45-a7f5-3d50fe12ce85
DOI
10.21203/rs.3.rs-3144744/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Homoharringtonine overcomes the negative impact of genetic patterns on venetoclax plus azacitidine regimen in relapsed/refractory acute myeloid leukemia: a multi-center, cohort studyDOI 10.21203/rs.3.rs-3144744/v1
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study.Semantic proximity
Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity
Venetoclax combined with hypomethylating agents and the CAG regimen (DCAG) in relapsed/refractory AML: A single- center clinical trialSemantic proximity
Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center studySemantic proximity
Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China.Semantic proximity
Safety and efficacy of venetoclax-azacitidine combined with low-dose idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real- world single-center experienceSemantic proximity
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimensSemantic proximity
Clinical Experience With Venetoclax in Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia.Semantic proximity
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentSemantic proximity
Efficacy of venetoclax and azacitidine based therapy in favorable-risk unfit acute myeloid leukemia: a real-world studySemantic proximity
Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan.Semantic proximity
Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity
Select a neighboring publication to make it the new centre.